AgingResearch.NewsJoin free

Cullinan Therapeutics

CompanyUnited States

Cullinan Therapeutics develops one asset, in phase 2 (CLN-049 in relapsed/refractory acute myeloid leukemia). Mostly antibody acting on FLT3; based in the United States.

1
Asset
Furthest stage
Phase 2
1
Trial
0
Signals

Pipeline

1

  • CLN-049

    T cell engager targeting FLT3

    Phase 2, Antibody, FLT3, relapsed/refractory acute myeloid leukemia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials1

Intelligence